New case study shows 64% of participants represent diverse populations
DENVER, May 15, 2025 /PRNewswire/ — While clinical trials have historically struggled with participation among underrepresented populations, EmVenio Research breaks the status quo. In a recent trial for a metabolic treatment for patients with obesity, the company exceeded participation goals among diverse patients, as highlighted in its latest case study. Patients from underrepresented populations made up 64% of the participants, far exceeding the national average of approximately 25%. This total for the trial so far includes 32% African American, 15% Hispanic and 12% Native American.
In 2020, participants in new drug trials were made up of only 8% Black individuals and 11% Hispanic individuals. Inclusivity among trial participants was a priority for this study, as obesity and diabetes rates vary greatly by race and ethnicity. Additionally, studies have shown that many individuals with obesity come from socioeconomically disadvantaged backgrounds, which often leads to limited access to clinical trials due to the significant time and commitment required from participants. In order to enroll inclusive patient populations for this trial, EmVenio researchers recruited participants through community outreach initiatives, including free health screenings conducted at the study site. The screenings also helped improve patient comfort, as many overweight and obese patients experience psychological distress in health care settings. EmVenio’s patient-centered approach fostered strong connections between patients and researchers, increasing the likelihood of patient enrollment and retention throughout the trial.
“Socioeconomic barriers hinder people from participating in clinical trials and are a major contributing factor to the lack of diversity in medical research, and we helped patients to explore options for their health and receive the best possible care,” said Thad Wolfram, Chief Strategy Officer of EmVenio. “EmVenio’s collaboration with fellow health care providers in these communities and our patient-first approach are what helped us generate an inclusive group of participants for this study, drawing in a more accurate representation of our nation’s cultural makeup.”
EmVenio’s case study discusses the team’s approach to recruit, enroll and retain patients from diverse backgrounds. To meet the sponsor’s inclusivity goals for the trial, EmVenio strategically opted to conduct study visits in Oklahoma City, Oklahoma, and Phoenix, Arizona. Both communities have a diverse cultural makeup of potential participants, and their respective social determinants of health revealed a robust number of patients who met the trial’s requirements and criteria.
For information on EmVenio’s inclusive, community-based approach to clinical trials, email contact@emvenio.com.
About EmVenio Research
EmVenio Research, a PCM Trials Company, provides a scalable network of clinical trial sites strategically located in underrepresented communities to engage inclusive patient populations. Our extensive global network comprises highly skilled clinicians, leading principal investigators, and cutting-edge research sites, allowing us to deliver high-quality clinical research services that prioritize reducing the burden on patient participation. Visit emvenio.com to learn more.
View original content to download multimedia:https://www.prnewswire.com/news-releases/emvenio-research-exceeds-diversity-goals-for-metabolic-disease-clinical-trial-302455703.html
SOURCE EmVenio Research
